Brown Advisory
ASND icon

Brown Advisory’s Ascendis Pharma A/S ASND Stock Holding History

Brown Advisory’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-24,544
Closed -$5.23M – 1397
2025
Q4 		$5.23M Sell
24,544
-789
-3% -$163K 0.01% 538
2025
Q3 		$5.04M Sell
25,333
-172
-0.7% -$32.1K 0.01% 530
2025
Q2 		$4.4M Sell
25,505
-355
-1% -$57.8K 0.01% 523
2025
Q1 		$4.03M Sell
25,860
-10,426
-29% -$1.49M 0.01% 524
2024
Q4 		$5M Sell
36,286
-431,366
-92% -$56.7M 0.01% 522
2024
Q3 		$69.8M Sell
467,652
-11,024
-2% -$1.49M 0.09% 170
2024
Q2 		$65.3M Sell
478,676
-205,396
-30% -$27.9M 0.09% 175
2024
Q1 		$103M Buy
684,072
+178,125
+35% +$25.4M 0.14% 129
2023
Q4 		$63.7M Sell
505,947
-4,162
-0.8% -$415K 0.09% 165
2023
Q3 		$47.8M Buy
510,109
+13,227
+3% +$1.24M 0.08% 195
2023
Q2 		$44.3M Buy
496,882
+30,510
+7% +$2.66M 0.07% 208
2023
Q1 		$50M Buy
466,372
+26,080
+6% +$2.98M 0.08% 191
2022
Q4 		$53.8M Sell
440,292
-197,709
-31% -$23M 0.1% 175
2022
Q3 		$65.9M Sell
638,001
-14,723
-2% -$1.4M 0.13% 144
2022
Q2 		$60.7M Buy
652,724
+133,112
+26% +$12.5M 0.11% 155
2022
Q1 		$61M Buy
519,612
+43,458
+9% +$5.03M 0.09% 176
2021
Q4 		$64.1M Buy
476,154
+54,927
+13% +$8.17M 0.08% 184
2021
Q3 		$67.1M Buy
421,227
+8,816
+2% +$1.21M 0.1% 163
2021
Q2 		$54.3M Buy
412,411
+109,989
+36% +$14.7M 0.08% 187
2021
Q1 		$39M Buy
302,422
+255,728
+548% +$38.9M 0.07% 212
2020
Q4 		$7.79M Buy
46,694
+8,253
+21% +$1.36M 0.01% 373
2020
Q3 		$5.93M Buy
38,441
+15,001
+64% +$2.16M 0.01% 383
2020
Q2 		$3.47M Buy
+23,440
New +$3.22M 0.01% 432
2019
Q2 		– Sell
-6,215
Closed -$732K – 1040
2019
Q1 		$732K Buy
+6,215
New +$544K ﹤0.01% 887

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Brown Advisory's ASND Position: Q1 2026 in Review

Brown Advisory sold out of Ascendis Pharma A/S (ASND) in Q1 2026, closing a stake of 24,544 shares — an estimated $5.23M sold.

Brown Advisory first reported a position in ASND in Q1 2019 and held it in 24 quarters. The position peaked at $103M in Q1 2024. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

  • Brown Advisory reported no remaining Ascendis Pharma A/S position as of Q1 2026 after selling out during the quarter.
  • Brown Advisory sold 24,544 Ascendis Pharma A/S shares in Q1 2026, an estimated $5.23M.
  • Brown Advisory first reported a position in Ascendis Pharma A/S in Q1 2019 and held it in 24 quarters.
  • Brown Advisory's Ascendis Pharma A/S position peaked at $103M in Q1 2024.
  • 273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Brown Advisory's 13F filing for Q1 2026, filed 15 May 2026.